Dear Reader,
In our current issue we are pleased to present three studies related to HPV: long-term follow-up on efficacy, immunogenicity and safety of Cervarix (Naud, p 2147), correlates of completion for the vaccine series among young adult female initiators (Rahman, p 2163) , and development of a competitive luminex immunoassay for various HPV types (Roberts, p 2168).
Several papers deal with Novel Vaccines: a review on strategies and applications for the control of pathogens and tumors at mucosal sites (Nizard, p 2175), studies on multivalent TB vaccines targeting the esx gene family (Villarreal, p 2188), aerosol delivery of TB vaccine AERAS-402/Ad35 (Hokey, p 2199), immune response to RTS,S/AS01-and AS02-adjuvanted malaria vaccines in malaria-naïve adults (Leroux-Roels, p 2211), characterization of the EV71 P1 polyprotein expressed in Pichia pastoris as a candidate vaccine (Han, p 2220), and nasal immunization with a mimovirus epitope-based vaccine inducing suppressed fertility in mice (Chen, p 2227). Two commentaries on enhancing poxvirus vector immunogenicity (García-Arriaza,p 2235), and dengue vaccines as a valuable future asset (Jindal, p 2245) round out this section.
The track on Rotavirus (RV) features five studies on safety and immunogenicity of pentavalent vaccine in healthy elderly subjects (Lawrence, p 2247), clinical and cost burden of RV infection in US children before and after introduction of RV vaccines (Krishnarajah, p 2255), RV gastroenteritis cases observed during the vaccination phase of the Rotavirus Efficacy and Safety Trial (Matson, p 2267), a post-marekting surveillance analysis of reactogenicity and safety of Rotarix (Bravo, p 2276), and burden and genotyping of RV disease in UAE (Howidi, p 2284). Finally, a commentary asks whether current cost-effectiveness analyses reflect the full value of childhood vaccination in Europe, using RV as the example (Brüggenjürgen, p 2290).
The Immunotherapy section contains a review on oral immunotherapy for the treatment of food allergy (Begin, p 2295), as well as several research papers on efficacy of virus-like particles presenting IL-33 in a mouse model of asthma (Long, p 2303), induction of leukocyte infiltration at metastatic sites mediating the protective effect of a NGcGM3-based cancer vaccine (Labrada, p 2312), preparation of egg yolk antibodies against botulinum neurotoxin BoNT/B and their passive protection in mouse models (You, p 2321), and thimerosal compromising human dendritic cell maturation, IL-12 production, chemokine release and T-helper polarization (Loison, p 2328).
Five studies fall into the category Hepatitis: absence of occult HBV infection in sera of diabetic children and adolescents following hepatitis B vaccination (Elrashidy, p 2336), cost-effectiveness of hepatitis A vaccination in Indonesia (Suwantika, p 2342), biodegradable polylactide microspheres enhance specific immune response induced by hepatitis B surface antigen (Qiu, p 2350), specific cellular immune responses induced by a novel hepatitis C genotype 1a/1b consenus DNA vaccine in Rhesus macaques (Latimer, p 2357), and identification and retrospective validation of T-cell epitopes in the HCV genotype 4 proteome (Abdel-Hady, p 2366).
Papers related to Influenza look at knowledge of and attitudes to influenza in unvaccinated primary care physicians and nurses (Domínguez, p 2378), immunogenicity of a A(H1N1)pdm09 vaccine in patients with hematological malignancies (Ide, p 2387), safety, immunogenicity and antibody persistence of MF59-adjuvanted and non-adjuvanted A/H1N1 vaccine in adults one year after vaccination (Reisinger, p 2395), and matrix MTM adjuvanted virosomal H5N1 vaccine inducing balanced T-cell responses in humans (Pedersen, p 2408).
The section on Licensed Vaccines features studies on one-dose vaccination associated with attenuated disease severity of adolescent and adult varicella cases (Zhang, p 2417), the relationship between meteorological factors and mumps incidence (Yang, p 2421), safety and immunogenicity of purified chick embryo cell rabies vaccine administered intradermally as post-exposure prophylaxis (Ravish, p 2433), immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine co-administered or administered sequentially to young girls (Gilca, p 2438), and an outbreak of mumps in a school setting in the UK (Aasheim, p 2446). A commentary in this section discusses the development of improved pertussis vaccine (Rumbo, p 2450).
Three contributions in the category Target Populations deal with inequalities in vaccination coverage for young females whose parents are informal caregivers (Offutt-Powell, p 2454), burden of vaccine-preventable disease in adult Medicaid and commercially insured populations (Krishnarajah, p 2460), and the need for introducing vaccines for the elderly into the Indian immunization program (Verma, p 2468),
The Meningococcal section features a study on safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia (Ilyina, p 2471), and a case report describing a Syrian patient diagnosed with meningococcal meningitis serogroup B (Tezer, p 2482).
One study on Vaccine Acceptance examines parent`s attitudes toward multiple vaccinations at a single doctor's visit with alternative delivery methods (Kaaijk, p 2483).
Our Technologies track features a research papers on the effect of cryopreservation of peripheral blood mononuclear cells on the variability of an antigen-specific memory B cell ELISpot assay (Trück, p 2490), as well as two commentaries discussing the cyanobacterium spirulina as a robust alternative biofactory system to plants for the production of edible vaccines (Barzegari, p 2497), and vaccine encapsulated in biodegradable nanoparticles as a model for mucosal delivery of a human vaccine (Sun, p 2503).
A commentary in our HIV section discussing the importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy (Montefiori, p 2507) rounds out this issue.
As always, we offer a selection of the latest news in the field of vaccines and immunotherapeutics in our monthly News, Policy and Profiles (NP&P) track. In this section we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. In the current issue we are pleased to present the portrait of Dr De-chu Tang, currently affiliated with the International Vaccine Institute in Seoul, South Korea. In his essay he summarizes important career milestones and shares his experience in developing DNA vaccines, skin-patch vaccines, adenovirus-vectored nasal influenza and anthrax vaccines, and the protective innate-adaptive immunity duo platform technology. Please contact Eva Riedmann with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome!
